Drug Profile
Research programme: cannabinoid therapeutics - GB Sciences
Alternative Names: BCTC - Makai Biotechnology; Cannabis-based neuroprotective compounds - GB Sciences; GBS-101; GBS-102; GBS-103; TRPV1 inhibitorsLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Catalent Pharma Solutions; University of Hawaii
- Developer GB Sciences; Makai Biotechnology; Michigan State University
- Class Analgesics; Anti-inflammatories; Antiparkinsonians; Antipsychotics; Antirheumatics; Anxiolytics; Cannabinoids; Cardiovascular therapies; Heart failure therapies; Muscle relaxants; Neuroprotectants; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators; TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Heart failure; Inflammation; Neuropathic pain; Parkinson's disease
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO, Controlled release)
- 28 Mar 2021 No recent reports of development identified for preclinical development in Inflammation in USA